NCT04851119 is a Phase 1, PHASE2 clinical trial of Biospecimen Collection in Colorectal Carcinoma, sponsored by Children's Oncology Group.

Who is sponsoring NCT04851119?

NCT04851119 is sponsored by Children's Oncology Group.

What drugs are being tested in NCT04851119?

Interventions in NCT04851119: Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint, X-Ray Imaging.

What condition does NCT04851119 study?

NCT04851119 studies Colorectal Carcinoma, Endometrial Carcinoma, Melanoma, Neuroblastoma, Ovarian Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Desmoid Fibromatosis, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Hepatocellular Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Refractory Desmoid Fibromatosis, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Hepatocellular Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Solid Pseudopapillary Neoplasm of the Pancreas, Wilms Tumor.

Is NCT04851119 still recruiting?

NCT04851119 is currently recruiting now. Last updated 24 February 2026.

Last reviewed 2026-02-24 · How we verify

NCT04851119

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Recruiting now Phase 1, PHASE2 Last updated 24 February 2026

What this trial tests

Phase 1, PHASE2 trial testing Biospecimen Collection in Colorectal Carcinoma in 147 participants. Currently enrolling.

Timeline

8 November 2021

Primary endpoint
30 June 2028

30 June 2028

Quick facts

Lead sponsor	Children's Oncology Group
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	147
Start date	8 November 2021
Primary completion	30 June 2028
Estimated completion	30 June 2028
Sites	21 locations across United States

Drugs / interventions tested

Biospecimen Collection — full drug profile →
Dual X-ray Absorptiometry — full drug profile →
Tegavivint — full drug profile →
X-Ray Imaging

Conditions studied

Colorectal Carcinoma — all drugs for Colorectal Carcinoma →
Endometrial Carcinoma — all drugs for Endometrial Carcinoma →
Melanoma — all drugs for Melanoma →
Neuroblastoma — all drugs for Neuroblastoma →

Sponsor

Children's Oncology Group — full company profile →

Who can join

Adults 12 Months to 30, any sex, with Colorectal Carcinoma or Endometrial Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of tumor cells by blocking the signals passed from one molecule to another inside a cell that tell a cell to grow.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Evolving strategies for management of desmoid tumor.
Riedel RF, Agulnik M. · · 2022 · cited 52× · PMID 35670122 · DOI 10.1002/cncr.34332
Desmoid Tumors: A Comprehensive Review.
Bektas M, Bell T, Khan S, Tumminello B, et al · · 2023 · cited 50× · PMID 37436594 · DOI 10.1007/s12325-023-02592-0
A New Wave of Targeting 'Undruggable' Wnt Signaling for Cancer Therapy: Challenges and Opportunities.
Park WJ, Kim MJ. · · 2023 · cited 34× · PMID 37190019 · DOI 10.3390/cells12081110
Deciphering the Signaling Mechanisms of Osteosarcoma Tumorigenesis.
Nirala BK, Yamamichi T, Yustein JT. · · 2023 · cited 32× · PMID 37511127 · DOI 10.3390/ijms241411367
Molecular pathogenesis of desmoid tumor and the role of γ-secretase inhibition.
Federman N. · · 2022 · cited 31× · PMID 36068332 · DOI 10.1038/s41698-022-00308-1
Current and Emerging Therapeutic Approaches for Extracranial Malignant Rhabdoid Tumors.
Nemes K, Johann PD, Tüchert S, Melchior P, et al · · 2022 · cited 31× · PMID 35173482 · DOI 10.2147/cmar.s289544
Epithelial-mesenchymal transition in colorectal cancer metastasis and progression: molecular mechanisms and therapeutic strategies.
Nie F, Sun X, Sun J, Zhang J, et al · · 2025 · cited 27× · PMID 40695791 · DOI 10.1038/s41420-025-02593-8
Children's Oncology Group's 2023 blueprint for research: Renal tumors.
Geller JI, Hong AL, Vallance KL, Evageliou N, et al · · 2023 · cited 22× · PMID 37477907 · DOI 10.1002/pbc.30586

Verify or expand the search:

Other trials of Biospecimen Collection

Trials testing the same drug.

NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting

Other recruiting trials for Colorectal Carcinoma

Currently open trials in the same condition.

NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I · Phase 2 · recruiting
NCT06557733 — An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis · Phase 2 · recruiting
NCT07291414 — A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients · NA · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT07192068 — Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration · Phase 2 · recruiting

Other Children's Oncology Group trials

Trials by the same sponsor.

NCT07412002 — Quality of End-of-Life Care for Children With Cancer · not yet recruiting
NCT07498465 — A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant · Phase 1 · withdrawn
NCT07022678 — Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia · Phase 3 · not yet recruiting
NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
NCT06858501 — Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04851119 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Children's Oncology Group
Last refreshed: 24 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04851119.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing